Several AURKB inhibitors have been investigated in phase 1–2 clinical trials, with success in some solid tumours, especially those with rapid cell turnover and dependency on efficient mitoses, such as small cell lung cancer (SCLC) [15–21]. This evidence concerns the gene AURKB and small cell lung carcinoma.